Santhera Licenses North American Rights For Parkinson's Drug To Biovail
This article was originally published in The Pink Sheet Daily
Executive Summary
The transaction is the Canadian drug maker's latest in a string of deals designed to increase its footing in the CNS market.
You may also be interested in...
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them